NAD+ (100mg / 500mg / 1000mg) appears in Mitochondrial Research catalogs for qualified buyers who need specification, COA, and RUO clarity—NAD+ Specification and Vial Format Review summarizes key checks.
NAD+ is nicotinamide adenine dinucleotide used in laboratory research on cellular redox systems, mitochondrial pathway models, coenzyme-dependent reactions, and metabolic signaling studies.
NAD+ serves as coenzyme for sirtuins, PARPs, and redox enzymes; exogenous NAD+ in culture supports sirtuin deacetylase activity assays and mitochondrial respiration studies. Research tracks NAD+/NADH ratios during aging cell models and reprogramming experiments requiring defined coenzyme concentrations.
Enzymatic cycling assays, sirtuin activity kits with acetylated peptide substrates, and LC-MS metabolomics quantify NAD+ pool dynamics. Sinclair lab and broader aging research literature use NAD+ precursors and NAD+ itself to probe sirtuin-dependent stress responses in cell models.
Side-by-side review of specification table, vial label, and COA prevents release errors for NAD+. Principal investigators should sign off NAD+ SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (100mg / 500mg / 1000mg) in procurement systems—do not round kit counts.
Catalog identifiers for NAD+: CAS 53-84-9, Formula: C21H27N7O14P2. MW 663.4 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for NAD+ to support reproducibility.
Dose planning for NAD+ should state mass (100mg / 500mg / 1000mg) or molarity derived from catalog molecular weight.
Molecular identifiers for NAD+—CAS 53-84-9, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing NAD+ should include these fields for reproducibility in Mitochondrial Research journals. Format selection for NAD+ affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for NAD+. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for NAD+ should state whether the lot COA must meet or exceed that threshold for your Mitochondrial Research assay type.
Specification alignment for NAD+ requires copying exact kit notation (100mg / 500mg / 1000mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for NAD+ should state whether the lot COA must meet or exceed that threshold for your Mitochondrial Research assay type. Specification alignment for NAD+ requires copying exact kit notation (100mg / 500mg / 1000mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for NAD+. QA sign-off should reference all four documents in the batch record.
NAD+ from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.